TCR² Therapeutics to Present at the SVB Leerink Global Healthcare Conference
February 09 2022 - 6:45AM
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell
therapy company with a pipeline of novel T cell therapies for
cancer patients suffering from solid tumors, today announced that
management will participate in a fireside chat at the 11th Annual
SVB Leerink Global Healthcare Conference on Wednesday, February 16
at 1:40PM E.T. using a virtual platform.
A live webcast of the presentation will be
available on the Investors page of the Company’s website at
www.investors.tcr2.com. An archived replay will be available for at
least 30 days following the presentation.
About TCR2
Therapeutics
TCR2 Therapeutics Inc. is a
clinical-stage cell therapy company developing a pipeline of novel
T cell therapies for cancer patients suffering from solid
tumors. The company is focused on the discovery and
development of product candidates against novel and complex targets
utilizing its proprietary T cell receptor (TCR) Fusion
Construct T cells (TRuC®-T cells). The TRuC platform is
designed to specifically recognize and kill cancer cells by
harnessing signaling from the entire TCR, independent of human
leukocyte antigens (HLA). For more information about TCR2, please
visit www.tcr2.com.
Investor and Media Contacts:
TCR2
Therapeutics
Carl MauchSenior Director, Investor Relations and Corporate
Communications(617) 949-5667carl.mauch@tcr2.com
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jun 2024 to Jul 2024
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jul 2023 to Jul 2024